ADORA2A and early-onset autosomal dominant Alzheimer disease: The adenosine A2A receptor (A2AR) has been studied as a potential therapeutic target in peripheral inflammatory diseases [1] and in brain disorders, such as depression [2], drug addiction [3], Alzheimer’s disease [4], and Parkinson’s disease [5].